We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

Hanmi's perseverance

15 0 0
Drugmaker's ceaseless R&D investment bears another fruit

Hanmi Pharmaceutical has succeeded in exporting new drug technology that could lead to another blockbuster. The Korean drugmaker entered into an exclusive licensing agreement recently with its U.S. partner MSD to commercialize a dual agonist, a candidate for a new hepatitis treatment, for 1.02 trillion won ($860 million). If the medicine hits the market, Hanmi will receive additional payments in royalties.

The contract was a victory for Hanmi's perseverance. The company initially developed the dual agonist for insulin secretion and........

© The Korea Times

Get it on Google Play